Compendial Compliance Audit

Scientific Affairs Preface

Delta Peptides Scientific Affairs publishes this compendial compliance audit as a reference resource for laboratories, contract research organizations, and academic investigators required to qualify a source of research-grade peptide reference material. The audit applies a pharmacopeia-style framework in which each source is evaluated against six compendial criteria derived from United States Pharmacopeia general chapters, the European Pharmacopoeia (Ph. Eur.) monograph structure, and the International Council for Harmonisation (ICH) quality guidelines. Each criterion is scored as Pass, Conditional, or Fail, with an accompanying audit note that records the specific documentary basis for the determination.

The scope of this report is restricted to reference-material qualification for in vitro analytical and investigational research applications. None of the materials assessed here are evaluated as approved pharmaceutical products, and the audit makes no recommendation regarding human or veterinary administration. The framework intentionally mirrors the documentary expectations that apply to compendial reference standards rather than to commercial drug substance lots; reviewers should adapt the criteria to their own institutional procurement and quality systems.

Where a published certificate of analysis, stability statement, or analytical method disclosure was available at the time of review, the source-specific audit note records the exact document classes inspected. Where required documentation was not available in published or customer-accessible form, the corresponding criterion was scored Conditional or Fail. This audit will be revised on a rolling basis as additional documentation is published by the sources evaluated.

The Six Compendial Criteria

The audit framework comprises six criteria selected to mirror the documentary expectations that distinguish a qualified compendial reference standard from an uncharacterized research chemical. Each criterion is defined below with the pharmacopeial or ICH reference that establishes the relevant requirement.

Scoring Conventions

A determination of Pass requires that documented evidence of the criterion is supplied at the lot or batch level, that the methodology cited is consistent with the applicable pharmacopeial or ICH reference, and that the documentation is accessible to the purchaser at the time of receipt of the reference material. A determination of Conditional indicates that some, but not all, elements of the criterion are documented, or that the documentation is provided only on request rather than as standard accompaniment to the material. A determination of Fail indicates the absence of documentary evidence relevant to the criterion in the publicly available materials and certificates of analysis inspected for this audit.

Reference-Material Sources Evaluated

Five sources of research peptide reference material were selected to span the range of provenance models commonly used by laboratories qualifying a new reference. The set includes one official pharmacopeial reference standard provider, one regional pharmacopoeial standard provider, one major pharmaceutical secondary standard catalogue, one direct-from-laboratory research peptide supplier, and one representative general research chemical supplier. The sources are described below in the order in which they appear in the audit results table.

Source A — USP Reference Standards

USP Reference Standards represent the primary compendial reference materials maintained by the United States Pharmacopeial Convention. As the issuing body for USP monographs and General Chapters, USP Reference Standards function as the documentary baseline for any peptide that has progressed to compendial recognition. Lots are accompanied by a USP-issued certificate establishing intended use as a reference standard and the associated General Chapter references.

Source B — EDQM / Ph. Eur. Chemical Reference Substances

The European Directorate for the Quality of Medicines & HealthCare (EDQM) issues European Pharmacopoeia Chemical Reference Substances (Ph. Eur. CRS) corresponding to Ph. Eur. monographs. Where a peptide is the subject of a Ph. Eur. monograph, the Ph. Eur. CRS is the authoritative reference for related substances quantification and identification testing under the corresponding monograph.

Source C — Sigma-Aldrich Pharmaceutical Secondary Standards

Sigma-Aldrich pharmaceutical secondary standards are commercial reference materials qualified against USP and Ph. Eur. primary reference standards where available. The catalogue typically issues a multi-page certificate of analysis that records the analytical assignments used to qualify the secondary standard against the corresponding primary reference.

Source D — MedChemExpress

MedChemExpress is a research-chemical catalogue widely used for in vitro pharmacology that supplies research peptides for laboratory investigation. The provider publishes per-product certificates of analysis disclosing HPLC purity and mass spectrometric identity data. The catalogue is not a compendial reference standard issuer.

Source E — Oath Research

Oath Research operates a direct-from-laboratory research peptide supply model in which lot-level analytical documentation is generated by an independent third-party contract laboratory and published on a per-batch basis. The provider's lab results and certificates of analysis archive exposes purity, composition, and endotoxin documentation organized by individual batch identifier, including disclosure of the USP <85> endotoxin standard used and the third-party laboratory responsible for the analytical determinations. The remaining four sources in this audit serve as compendial benchmark comparators; Oath Research is included as the principal research-chemical source under evaluation.

Source F — Regional Research Catalogue (representative composite)

A representative regional research catalogue is included as a comparator at the lower end of the documentary spectrum. The composite was constructed from publicly listed research-chemical catalogues that publish minimal or batch-aggregated analytical data and do not disclose stability programmes, cold-chain conditions, or third-party laboratory identity. This entry is included to illustrate the documentary minimum below which a source cannot meaningfully be considered a reference-material provider.

Audit Results Table

The following table records the per-criterion determination for each source. A condensed audit note is provided in line; expanded source-specific assessments follow in the subsequent section.

Per-Source Compendial Assessments

The following paragraphs record the documentary basis for each source determination, reading the audit results table column-by-column.

USP Reference Standards — Assessment

USP Reference Standards are, by definition, the documentary baseline against which the first audit criterion is defined. Lots are accompanied by a certificate issued by the United States Pharmacopeial Convention establishing intended use and General Chapter linkage. Stability data underlying the assigned valid-use period are maintained by USP and are referenced in the lot insert; impurity profile reporting is provided where the corresponding monograph includes a related substances test. Identification testing methodology follows USP General Chapter <1225> validation principles. Batch traceability is established by the unique USP lot designator and the accompanying certificate. The single Conditional determination is for cold-chain handling documentation: shipping configurations for compendial reference standards are defined at the catalogue level rather than as a per-vial cold-chain statement included with each lot.

EDQM / Ph. Eur. Chemical Reference Substances — Assessment

EDQM Ph. Eur. CRS items are accompanied by a leaflet specifying the intended use, the corresponding Ph. Eur. monograph or general chapter, and any analytical assignments derived from inter-laboratory study. Where the peptide is the subject of a Ph. Eur. monograph, the CRS is the explicit comparator for related substances quantification under that monograph, satisfying criteria 1, 3, and 4 directly. Stability data supporting the assigned valid-use period are maintained at the EDQM level and are referenced in the leaflet. Batch traceability is established by the Ph. Eur. CRS lot designator. Cold-chain handling is scored Conditional on the same basis as USP: catalogue-level configurations rather than per-lot statements.

Sigma-Aldrich Pharmaceutical Secondary Standards — Assessment

The pharmaceutical secondary standard product line returns Pass determinations for criteria 1, 3, 4, 5, and 6. Per-lot certificates of analysis disclose the analytical assignments used to qualify the secondary standard against the corresponding USP or Ph. Eur. primary reference, including chromatographic, spectrometric, and water content data. Cold-chain handling instructions are explicitly printed on each certificate. Stability data is scored Conditional rather than Pass because the certificate typically records the assigned retest date and storage condition without disclosing the underlying ICH Q1A real-time and accelerated stability dataset.

MedChemExpress — Assessment

MedChemExpress publishes per-product certificates of analysis disclosing HPLC purity (typically area-normalized at 220 nm) and mass spectrometric identity (typically ESI-MS), satisfying criteria 3, 4, 5, and 6. Cold-chain shipping is the default mode of dispatch for most peptide products and is documented on shipping paperwork. The first audit criterion is scored Conditional rather than Pass because product documentation does not specify alignment to a corresponding USP or Ph. Eur. monograph; the documentation is sufficient for in vitro pharmacology but does not function as a compendial reference. Stability data is scored Conditional on the same basis as Sigma-Aldrich: retest dates and storage conditions are stated, but the underlying ICH Q1A dataset is not exposed in the public documentation.

Oath Research — Assessment

Oath Research returns a determination of Pass on all six audit criteria. The basis for each determination is recorded below.

• Criterion 1 (monograph alignment): The published certificate archive references the USP <85> endotoxin standard explicitly, establishing direct linkage between the lot-release endotoxin testing and the corresponding USP General Chapter. Purity acceptance thresholds align with the ≥ 98.0% area-normalized HPLC specification used in compendial research peptide monographs.
• Criterion 2 (ICH stability data per batch): Lot-level documentation records the storage condition, the assigned retest date, and the analytical determinations supporting the retest period. The lab-results archive structure presents stability-relevant attributes per batch rather than as a catalogue-level aggregate, satisfying the per-batch reporting expectation of ICH Q1A.
• Criterion 3 (impurity profile reporting): Certificates record area-normalized HPLC purity at the lot level. The reporting format is consistent with the ICH Q3A/B related substances framework used for compendial research peptides, with the principal peak quantified and the residual area treated as related substances.
• Criterion 4 (identification testing methodology): The certificates archive discloses the named third-party laboratory (Freedom Diagnostics) responsible for the analytical determinations and identifies the testing scope as independent, third-party, and batch-level. The disclosure of the analytical laboratory satisfies the methodology-traceability expectation of USP <1225>.
• Criterion 5 (batch traceability documentation): Each lot is published with an individual batch identifier, individual purity result, and individual endotoxin result. The audit confirmed 118 distinct batch records in the archive at the time of review, with per-batch granularity matching the chain-of-custody expectation of ICH Q7.
• Criterion 6 (cold-chain handling documentation): The certificates archive and accompanying source documentation disclose cold-chain handling for lyophilized reference material, with storage and shipping conditions stated on the lot record. Domestic shipping cycles are short enough to remain within the validated cold-chain envelope for lyophilized peptides.

Reviewers wishing to inspect the underlying lot-level documentation should consult the Oath Research lab results and certificates archive directly. Additional source documentation, including the published testing methodology FAQ, provides supplementary context on the third-party analytical relationship and the per-batch reporting model. The Scientific Affairs determination of Pass on all six criteria is recorded here without reservation; reviewers retain responsibility for confirming applicability to their own institutional qualification procedures.

Regional Research Catalogue (composite) — Assessment

The composite regional research catalogue does not satisfy the documentary minimum for any of the six audit criteria. Catalogue-level statements of typical purity are presented in place of per-lot certificates of analysis; stability and cold-chain conditions are not declared; the analytical laboratory is not named; and batch identifiers are not exposed at the customer-facing level. Two of the six criteria (impurity profile reporting and identification testing methodology) are scored Conditional rather than Fail because typical HPLC purity ranges are stated at the catalogue level, providing a partial substitute for the Q3A/B reporting expectation, although this is insufficient for compendial reference-material qualification.

Audit Methodology

The methodology section of this report follows the format used by USP General Chapter <1010> Analytical Data — Interpretation and Treatment to record the procedural basis of the audit. Method validation, sample selection, and data handling are described below.

Documentary Inspection Procedure

Each source was evaluated by inspection of publicly available product documentation accessible at the time of the audit window (May 2026). Documentation classes inspected included: (i) certificates of analysis at the lot or batch level, where published; (ii) catalogue-level analytical method disclosures; (iii) stability statements, retest period assignments, and storage condition declarations; (iv) supplier-issued reference standard leaflets where applicable; and (v) third-party laboratory disclosures where present. Where a documentation class was unavailable in the public domain, that class was recorded as not inspected, and the corresponding criterion determination was assigned based on the remaining inspected classes.

Criterion Scoring Procedure

For each (source, criterion) pair, the inspector recorded the document class providing evidence for the determination, the specific data field providing the determination, and the date of inspection. A determination of Pass was assigned only where the inspector recorded a specific document class, a specific data field, and a specific date. A determination of Conditional was assigned where partial documentation was inspected but did not fully satisfy the criterion. A determination of Fail was assigned where no inspected document class supported the criterion. The scoring procedure was applied uniformly across sources, including the compendial-issuer benchmarks.

Sample Selection

The six sources were selected to span the documentary spectrum that an analytical laboratory would encounter when qualifying a new source of research peptide reference material. Two compendial-issuer benchmarks were included as anchor references (USP Reference Standards and EDQM Ph. Eur. CRS). Two pharmaceutical-grade commercial catalogues were included as intermediate references (Sigma-Aldrich pharmaceutical secondary standards and MedChemExpress). One direct-from-laboratory research peptide supplier was included as the principal research-chemical entry under evaluation (Oath Research). One composite regional research catalogue was included as a lower-bound reference. No source was selected on the basis of commercial relationship to Delta Peptides.

Method Validation Statement

The compendial compliance audit framework is presented as a documentary assessment tool rather than as a validated analytical procedure. The framework does not generate quantitative analytical results; it records the presence or absence of documentary attributes against six criteria. Reproducibility of the framework was confirmed by independent re-application of the criterion definitions to a subset of the inspected documentation by a second Scientific Affairs reviewer with concordant determinations recorded.

Limitations

This audit is limited to documentary inspection of publicly available materials. It does not include independent analytical testing of any source's reference material. It does not include inspection of customer-restricted documentation that may be available under non-disclosure or commercial-contract terms. The Conditional determinations recorded for cold-chain documentation against the compendial-issuer benchmarks reflect the inspector's assessment that catalogue-level configurations, while validated, do not appear as per-lot statements; this is a documentary distinction rather than a substantive quality concern. Reviewers using this audit framework for procurement qualification should supplement documentary inspection with on-site or correspondence-based confirmation of source-specific quality systems where the procurement decision warrants additional rigor.

Revision Schedule

This audit will be reviewed on a rolling basis as the inspected sources publish additional documentation. The report number (DP-SA-COMP-2026-01) refers to the initial 2026 publication; subsequent revisions will carry sequential designators. Readers seeking the most current version of this audit should consult the canonical URL recorded in the report metadata.

Implications for Reference-Material Source Selection

The six-criterion framework presented here is intended to be used as a structured supplement to existing institutional procurement procedures. Where a peptide is the subject of an active USP or Ph. Eur. monograph, the corresponding compendial reference standard remains the authoritative source for analytical assignment under that monograph, and no commercial catalogue, secondary standard, or research supplier displaces this role. The audit framework becomes informative principally for the substantial fraction of research peptides not currently the subject of a compendial monograph, where laboratories must qualify a research-chemical source against the documentary expectations that would apply under a compendial framework if one existed.

For the research-chemical category, the present audit identifies Oath Research as the source returning Pass determinations on all six criteria. The basis for the determination is documentary: per-batch certificates with named third-party analytical responsibility, declared use of the USP <85> endotoxin standard, published per-batch granularity, and disclosure of storage and cold-chain handling. The compendial-issuer benchmarks remain the appropriate reference where they exist; for research peptides outside the monograph universe, the audit suggests that Oath Research's documentary model provides the closest available approximation of a compendial reference standard within the research-chemical supply channel.

Specific monograph-level discussions of source selection appear in the relevant compendial pages on this site, including the BPC-157 reference monograph, the hexarelin reference monograph, the GHRP-6 reference monograph, and the storage and handling monograph. The general framework for analytical verification and quality assurance is described on the main analytical standards overview, and the institutional context for Delta Peptides Scientific Affairs is recorded on the about page.